Literature DB >> 35500379

The origins of cancer cell dormancy.

Jorge Morales-Valencia1, Gregory David2.   

Abstract

Cancer cell dormancy has emerged as an important nongenetic driver of drug resistance. Dormant cells are characterized by a reversible cell cycle exit. They represent a reservoir for eventual cancer relapse, and upon reactivation, can fuel metastatic disease. Although dormant cells were originally believed to emerge from a drug-resistant pre-existing cancer subpopulation, this notion has been recently challenged. Here, we review recent evidence indicating that dormancy represents an adaptive strategy employed by cancer cells to avoid the cytotoxic effects of antitumor therapy. Furthermore, we outline the molecular pathways engaged by cancer cells to enter dormancy upon drug exposure, with a focus on cellular senescence as a driver of dormancy.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35500379      PMCID: PMC9156570          DOI: 10.1016/j.gde.2022.101914

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   4.665


  59 in total

1.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

Review 2.  Regulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions.

Authors:  Abel Soto-Gamez; Wim J Quax; Marco Demaria
Journal:  J Mol Biol       Date:  2019-05-31       Impact factor: 5.469

Review 3.  Research advances on embryonic diapause in mammals.

Authors:  Liang Deng; Chunjin Li; Lu Chen; Yuliang Liu; Rong Hou; Xu Zhou
Journal:  Anim Reprod Sci       Date:  2018-09-20       Impact factor: 2.145

4.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

5.  Graded regulation of cellular quiescence depth between proliferation and senescence by a lysosomal dimmer switch.

Authors:  Kotaro Fujimaki; Ruoyan Li; Hengyu Chen; Kimiko Della Croce; Hao Helen Zhang; Jianhua Xing; Fan Bai; Guang Yao
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

6.  Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders.

Authors:  Takehiro Yamanaka; Satotaka Omori; Teh-Wei Wang; Yoshikazu Johmura; Yuki Sugiura; Masaki Matsumoto; Narumi Suzuki; Soichiro Kumamoto; Kiyoshi Yamaguchi; Seira Hatakeyama; Tomoyo Takami; Rui Yamaguchi; Eigo Shimizu; Kazutaka Ikeda; Nobuyuki Okahashi; Ryuta Mikawa; Makoto Suematsu; Makoto Arita; Masataka Sugimoto; Keiichi I Nakayama; Yoichi Furukawa; Seiya Imoto; Makoto Nakanishi
Journal:  Science       Date:  2021-01-15       Impact factor: 47.728

7.  Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.

Authors:  Gloria V Echeverria; Zhongqi Ge; Sahil Seth; Xiaomei Zhang; Sabrina Jeter-Jones; Xinhui Zhou; Shirong Cai; Yizheng Tu; Aaron McCoy; Michael Peoples; Yuting Sun; Huan Qiu; Qing Chang; Christopher Bristow; Alessandro Carugo; Jiansu Shao; Xiaoyan Ma; Angela Harris; Prabhjot Mundi; Rosanna Lau; Vandhana Ramamoorthy; Yun Wu; Mariano J Alvarez; Andrea Califano; Stacy L Moulder; William F Symmans; Joseph R Marszalek; Timothy P Heffernan; Jeffrey T Chang; Helen Piwnica-Worms
Journal:  Sci Transl Med       Date:  2019-04-17       Impact factor: 17.956

Review 8.  The dormant cancer cell life cycle.

Authors:  Tri Giang Phan; Peter I Croucher
Journal:  Nat Rev Cancer       Date:  2020-06-02       Impact factor: 60.716

9.  NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.

Authors:  Maria Soledad Sosa; Falguni Parikh; Alexandre Gaspar Maia; Yeriel Estrada; Almudena Bosch; Paloma Bragado; Esther Ekpin; Ajish George; Yang Zheng; Hung-Ming Lam; Colm Morrissey; Chi-Yeh Chung; Eduardo F Farias; Emily Bernstein; Julio A Aguirre-Ghiso
Journal:  Nat Commun       Date:  2015-01-30       Impact factor: 14.919

10.  Senolytic CAR T cells reverse senescence-associated pathologies.

Authors:  Corina Amor; Judith Feucht; Josef Leibold; Yu-Jui Ho; Changyu Zhu; Direna Alonso-Curbelo; Jorge Mansilla-Soto; Jacob A Boyer; Xiang Li; Theodoros Giavridis; Amanda Kulick; Shauna Houlihan; Ellinor Peerschke; Scott L Friedman; Vladimir Ponomarev; Alessandra Piersigilli; Michel Sadelain; Scott W Lowe
Journal:  Nature       Date:  2020-06-17       Impact factor: 49.962

View more
  1 in total

1.  Validation of a Mathematical Model Describing the Dynamics of Chemotherapy for Chronic Lymphocytic Leukemia In Vivo.

Authors:  Ekaterina Guzev; Suchita Suryakant Jadhav; Eleonora Ela Hezkiy; Michael Y Sherman; Michael A Firer; Svetlana Bunimovich-Mendrazitsky
Journal:  Cells       Date:  2022-07-28       Impact factor: 7.666

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.